May 11, 2018

Authors W. Pluskiewicz1, B. Drozdzowska, P. Adamczyk, K. Noga

Partial Abstract:

Summary The study presents the research output of 40 globally top-ranked authors, publishing in the field of osteoporosis. Their hindex is compared with the Scientific Quality Index (SQI), a novel indicator. Using SQI, 92.5% of the authors changed their initial positions in the general ranking. SQI partially depends on bibliometric measures different from those influencing h-index and may be considered as an assessment tool, reflecting more objective, qualitative, rather than quantitative, features of individual scientific output. Purpose The study approaches the research output of 40 globally top-ranked authors in the field of osteoporosis. Methods The assessed authors were identified in the Scopus database, using the key word Bosteoporosis^ and the h-index data, collected during the last decade (2008–2017). The data, concerning the scientific output, expressed by the h-index, were compared with a novel indicator of scientific quality—called the Scientific Quality Index (SQI). SQI is calculated according to the following formula: Parameter No. 1 + Parameter No. 2, where: Parameter No. 1 (the percent of papers cited ≥ 10 times) the number of papers cited ≥ 10 times (excluding self-citations and citations of all co-authors) is divided by the number of all the published papers (including the papers with no citation) × 100%, Parameter No. 2 (the mean number of citations per paper) the total number of citations (excluding self citations and citations of all co-authors) divided by the number of all published papers (including papers with no citation).

To read the full abstract and link to the article at the Archives of Osteoporosis (2018) 13:35

Open Access This article is distributed under the terms of the Creative Commons At tribution 4.0 International License (http:/ /, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.


May 08, 2018

Few pooled analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture reduction. Such information would be useful to assess new ARs or novel dosing regimens. In the Foundation for the National Institutes of Health (FNIH) Bone Quality project, we analyzed individual-level data from 28,000 participants enrolled in 11 bisphosphonate (BP) and three selective estrogen receptor modulator (SERM) placebo-controlled fracture endpoint trials. Using BTM results for two bone formation markers (bone-specific alkaline phosphatase [bone ALP] and pro-collagen I N-propeptide [PINP]) and two bone resorption markers (N-terminal and C-terminal telopeptide of type I collagen) and incident fracture outcome data, we performed a meta-regression relating the mean net effect of treatment on change in bone turnover (active minus placebo % difference after 3 to 12 months) to the log of study-wide fracture risk reduction, and used linear regression to plot the best fitting line. Separate analyses were performed for incident morphometric vertebral, nonvertebral, and hip fractures over 1 to 4 years of followup. Change in bone ALP and PINP were available for over 16,000 and 10,000 participants, respectively. For vertebral fracture, the results showed a strong relationship between treatment-related bone ALP or PINP changes and vertebral fracture risk reduction (r2¼0.82 [p<0.001] and r2¼0.75 [p¼0.011], respectively) Relationships were weaker and no longer statistically significant for nonvertebral (r2¼0.33 [p¼0.053] and r2¼0.53 [p¼0.065], respectively) and hip fracture (r2¼0.17 [p¼0.24] and r2¼0.43 [p¼0.11], respectively) outcomes. Analyses limited to BP trials gave similar results. For all fracture types, relationships were weaker and nonsignificant for bone resorption markers. We conclude that short-term AR treatment-related changes in bone ALP and PINP strongly predict vertebral fracture treatment efficacy, but not nonvertebral or hip fracture treatment efficacy. Change in bone formation markers might be useful to predict the anti-vertebral fracture efficacy of new AR compounds or novel dosing regiments with approved AR drugs

Accepted manuscript online December 6, 2017.
Address correspondence to: Douglas Bauer, MD, Department of Medicine, UCSF School of Medicine, 1545 Divisadero Street, San Francisco, CA 94115, USA.

Journal of Bone and Mineral Research, Vol. xx, No. xx, Month 2017, pp 1–9 DOI: 10.1002/jbmr.3355


May 02, 2018

Robert A. Hiatt, MD, PhD, professor in the Department of Epidemiology and Biostatistics, is first author on the paper describing the project's early progress and collaborations.  The paper also presents a framework for systematically planning and developing a similar structure for community-based health projects.

The San Francisco Cancer Inititiative is targeting the five most common cancers which account for half of all new cancers in San Francisco: breast, lung and other tobacco-related cancers, prostate, colorectal and liver cancer.

Read the full story at or read the paper in Health Affairs.   Read more about the San Francisco Cancer Initiative (SF CAN).


April 30, 2018

The Eureka Research Platform is designed to help investigators conduct direct-to-participant longitudinal research, including cohort studies and randomized controlled trials.  The platform uses technology developed for the Health eHeart Study, and enables eConsent, online surveys, collection of data from wearable sensors, devices and smartphones, and flexible messaging for reminders and behavioral interventions.  Integration with medical records is coming soon.  Learn more about the platform here.


March 02, 2018

The Osteoporotic Fractures in Men (MrOS) Study, a study of healthy aging with a focus on osteoporosis and fractures in 5,994 older men 65 years and older, has released over 16 years of prospective data on MrOS Online


MrOS Online provides data, documentation, and study procedures from the multi-center MrOS Study.  With over 41,000 variables across seven time points, the MrOS Online database includes:


  • Assessment of falls, fractures, and mortality
  • Performance tests and lifestyle questionnaires
  • Objective and subjective measures of physical activity
  • Data from x-ray images, DXA, QCT, and HRpQCT scans
  • Objective and subjective sleep data from the MrOS Sleep ancillary study (n=3,135)
  • Tracking of cardiovascular events from the MrOS Sleep ancillary study
  • Oral health assessments from the MrOS Dental ancillary visit (n=1,353)
  • Biospecimen data, including serum chemistry, hormones, and cytokines


The online database is available to the public and anyone who registers and accepts the terms of an online data use agreement can download or explore study data. Please note that only a subset of datasets from the MrOS archives are currently available online. Additional datasets will be publicly released in the near future.


The NIA blog/announcement can be found here:


October 03, 2017

Clinical trials of new drugs for the prevention of fracture are extremely expensive and typically go on for at least 3 years. Investigators have tried for decades to find a new more efficient way of conducting these trials more efficiently. The Foundation for NIH project on Bone Quality at the SFCC has discovered that hip BMD is a good surrogate for hip fracture in clinical trials.

The project has compiled data from over 100,000 participants in over 40 clinical trials. They have pooled all of this data together to create the most powerful existing tool for studying ways to make clinical trials more efficient. The project compared changes in hip BMD during the course of these trials and the change in risk of hip fracture. The scientists discovered that every 1% improvement in hip BMD in the trials accurately predicted about a 5% decrease in the risk of hip fractures. This result was presented at a recent conference held by the FDA about new guidelines for clinical trials and has been submitted to FDA to consider revising their guidelines to accept BMD as a “surrogate” to allow clinical trials to use hip BMD as an endpoint for trials to approve drug therapies for prevention of fracture. This would be a revolutionary change in approval of new treatments for osteoporosis.


October 03, 2017

High levels of mitochondrial DNA (mtDNA) heteroplasmy, a mixture of normal and mutated mtDNA molecules in a cell, lead to inherited mitochondrial diseases with neurological, sensory, and movement impairments. We measured mtDNA heteroplasmy at twenty disease-causing sites for associations with neurosensory and mobility function among elderly participants from a community-based study of aging.


May 01, 2016

In a study from MrOS from the SF Coordinating Center and led by Dr. Doug Bauer, we found that high levels of thyroid hormone that were not known to the patient or physician, indicated a 2.5 to 3.6 times greater chance of becoming frail later in life. This is a treatable condition that might lead to wasting bone and muscle.

(See abstract Virginii VS, et al. Subclinical thyroid dysfunction and frailty among older men. J Clin Endocrinol Metab 2015;100:4524-32.)